Alembic Pharmaceuticals Ltd. Revenue Rises 26% to ₹2,150 Crore

Alembic Pharmaceuticals Limited reported revenue of ₹2,150 crore in Q1 FY27, a 26% year-on-year increase, supported by 33% growth in its active pharmaceutical ingredients business and 7% growth in India branded formulations.

What did Alembic Pharmaceuticals report in Q1 FY27?

Alembic Pharmaceuticals reported a strong rise in quarterly revenue and operating profitability in Q1 FY27. Revenue reached ₹2,150 crore, compared with ₹1,711 crore in Q1 FY26, based on the company’s quarterly investor presentations. The latest quarter’s growth rate was 26% year-on-year.

The company reported EBITDA before research and development expenditure of ₹523 crore, with a margin of about 24%. Research and development spending represented 9% of revenue. Reported profit after tax stood at ₹173 crore, translating to a net profit margin of 8%.

The presentation also said post-R&D EBITDA increased 21% year-on-year. Alembic Pharmaceuticals attributed the profitability performance to operating leverage expansion while continuing planned investment in its US branded business and research pipeline, including peptide development and increased product filings.

The financial update is relevant because the company operates across domestic branded formulations, US and other international generics, and APIs. Growth across these businesses can influence both its scale and the level of investment required for product development and market expansion.

Which businesses supported the quarterly growth?

Alembic Pharmaceuticals said the API business grew 33% year-on-year, supported by a strong order book. APIs are the chemical ingredients used in finished medicines, and this business supplies customers in more than 60 countries, according to the presentation.

The India branded business recorded quarterly revenue of ₹641 crore, up 7% year-on-year. This segment sells branded formulations in the domestic market and remains an important part of the company’s operating base. Alembic Pharmaceuticals has more than 5,800 medical representatives working across 21 marketing divisions.

The company is ranked 21st in the Indian Pharmaceutical Market and reported a 1.1% share of the Indian pharma market. It also said five flagship brands have crossed annual sales of ₹100 crore each. These indicators show the scale of its domestic commercial operations, although the presentation did not provide individual brand-wise sales.

About 13% of the company’s product portfolio is listed under the National List of Essential Medicines, or NLEM. Products under the NLEM are subject to pricing provisions, making portfolio composition relevant to domestic formulations companies.

How does Q1 FY27 compare with earlier quarters?

Alembic Pharmaceuticals’ Q1 FY27 revenue of ₹2,150 crore was higher than the ₹1,711 crore reported in Q1 FY26. In that earlier quarter, the company recorded EBITDA of ₹288 crore, an EBITDA margin of about 17%, and net profit of ₹155 crore.

The India branded business grew from ₹599 crore in Q1 FY26 to ₹641 crore in Q1 FY27. The growth rate for this business increased from 5% in the earlier period to 7% in the latest reported quarter. API performance also improved from broadly flat growth of 1% in Q1 FY26 to 33% growth in Q1 FY27.

In Q1 FY26, the company said API revenue was affected by price erosion, though volume growth partly offset that pressure. The Q1 FY27 presentation instead cited a strong order book as support for the API business. The presentations do not provide a segment-wise revenue breakdown for APIs or international formulations.

Why do R&D and international expansion matter for Alembic Pharmaceuticals?

Alembic Pharmaceuticals is pursuing product development and overseas expansion alongside its established India formulations business. The company said its current plans include strategic expansion in the US branded business, a peptide-focused R&D pipeline, and increased product filings.

The company is also developing a specialty drug pipeline for India and exploring injectable opportunities. Its international strategy includes expansion of the product portfolio in the United States, strengthening its presence in Canada, and an established presence in Chile and the UAE.

R&D spending was 9% of Q1 FY27 revenue, compared with 8% in Q1 FY26 and 10% in Q2 FY26, according to the cited presentations. This expenditure is material because pharmaceutical product development and regulatory filings require sustained investment before products can contribute to commercial sales.

The company’s manufacturing footprint has also been expanded in recent periods. Its presentation for Q4 FY25 stated that the Indore facility was completed and commercial production began in April 2025. The current presentation does not quantify the facility’s contribution to Q1 FY27 revenue.

How does the quarterly performance affect investors and industry participants?

For investors, the main reported changes are the 26% revenue increase, 33% API growth and an EBITDA-before-R&D margin of about 24%. The increase in profitability occurred alongside continuing expenditure on R&D and planned expansion, rather than after a reduction in those strategic activities.

For the domestic pharmaceutical market, Alembic Pharmaceuticals’ 7% growth in branded formulations indicates continued expansion from a business with a 1.1% market share. Its 21 marketing divisions and more than 5,800 medical representatives provide a distribution and promotion network for its India portfolio.

For customers and healthcare providers, the company’s operations span APIs and finished dosage forms, including tablets, injections and creams. Its presence in both ingredient supply and formulations can support its product operations, but the presentation does not disclose product availability, prices or customer-level impacts during the quarter.

The API order book is also relevant to industry operations because API demand can be affected by customer procurement cycles, volumes and pricing. Alembic Pharmaceuticals reported the order book as a growth support, but did not state its value, duration or major customer mix.

Conclusion

Alembic Pharmaceuticals delivered a higher-revenue Q1 FY27, with revenue rising 26% to ₹2,150 crore. API growth of 33%, domestic branded business growth of 7%, and EBITDA before R&D of ₹523 crore were the central operating indicators in the company’s presentation. Reported profit after tax was ₹173 crore, while R&D remained 9% of revenue.

The next areas to watch are the company’s disclosed expansion in US branded products, peptide-focused development work, increased product filings and the specialty and injectable opportunities it is evaluating. The company has also highlighted its API order book, but has not provided its size or a timeline for conversion into revenue.